1、gPfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS GuidanceStrengthened Commercial Execution Driving Topline GrowthContinued Progress Across R&D PipelineExpanded Programs On Track to Deliver Net Cost Savings TargetsNEW YORK,Tuesday,August 5,2025 Pfizer Inc.(NYSE:PFE)reported fina

2、ncial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1)for Adjusted(2)diluted EPS.EXECUTIVE COMMENTARYDr.Albert Bourla,Chairman and CEO of Pfizer:“Pfizer had another strong quarter of focused execution and were pleased with our progress in adva

3、ncing our R&D pipeline,driving our commercial performance and expanding our margins.We continue to strengthen our company for the future and were confident in our ability to create further value for patients and our shareholders.”David Denton,CFO and EVP of Pfizer:“Our robust second-quarter Revenue

4、and EPS performance demonstrates our continued focus on commercial execution and operational efficiency.We raised our full-year 2025 Adjusted diluted EPS guidance,demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for shareholders.”OVERALL

5、RESULTSSecond-Quarter 2025 Revenues of$14.7 Billion,Representing 10%Year-over-Year Operational GrowthSecond-Quarter 2025 Reported(3)Diluted EPS of$0.51,and Adjusted(2)Diluted EPS of$0.78Reaffirms Full-Year 2025 Revenue Guidance(1)in a Range of$61.0 to$64.0 BillionRaises Full-Year 2025 Adjusted(2)Dil

6、uted EPS Guidance(1)by$0.10 to a Range of$2.90 to$3.10,which Absorbs a One-Time Impact of Approximately$0.20 Related to 3SBio TransactionOn Track to Deliver Approximately$7.2 Billion in Overall Anticipated Net Cost Savings from Previously Announced Cost Improvement Initiatives(4)by End of 2027,Drivi